Modeyso is a drug owned by Chimerix Inc. It is protected by 7 US drug patents filed in 2025 out of which none have expired yet. Modeyso's patents will be open to challenges from 06 August, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 30, 2037. Details of Modeyso's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10172862 | NA |
Jan, 2037
(11 years from now) | Active |
| US12102639 | NA |
Jan, 2037
(11 years from now) | Active |
| US10369154 | NA |
Jan, 2037
(11 years from now) | Active |
| US11976068 | NA |
Mar, 2036
(10 years from now) | Active |
| US9265765 | NA |
Jul, 2034
(8 years from now) | Active |
| US9629842 | NA |
Apr, 2032
(6 years from now) | Active |
| USRE46290 | NA |
Apr, 2032
(6 years from now) | Active |
FDA has granted several exclusivities to Modeyso. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Modeyso, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Modeyso.
Exclusivity Information
Modeyso holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Modeyso's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2030 |
US patents provide insights into the exclusivity only within the United States, but Modeyso is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Modeyso's family patents as well as insights into ongoing legal events on those patents.
Modeyso's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Modeyso's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 30, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Modeyso Generics:
There are no approved generic versions for Modeyso as of now.
About Modeyso
Modeyso is a drug owned by Chimerix Inc. Modeyso uses Dordaviprone Hydrochloride as an active ingredient. Modeyso was launched by Chimerix in 2025.
Approval Date:
Modeyso was approved by FDA for market use on 06 August, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Modeyso is 06 August, 2025, its NCE-1 date is estimated to be 06 August, 2029.
Active Ingredient:
Modeyso uses Dordaviprone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Dordaviprone Hydrochloride ingredient
Dosage:
Modeyso is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 125MG BASE | CAPSULE | Prescription | ORAL |